Bio-Path (BPTH) Competitors $0.16 -0.02 (-8.82%) As of 03/28/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. NLSP, SNOA, ENSC, ONVO, PWUP, KZIA, CMND, CPHI, ADIL, and APMShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include NLS Pharmaceutics (NLSP), Sonoma Pharmaceuticals (SNOA), Ensysce Biosciences (ENSC), Organovo (ONVO), PowerUp Acquisition (PWUP), Kazia Therapeutics (KZIA), Clearmind Medicine (CMND), China Pharma (CPHI), Adial Pharmaceuticals (ADIL), and Aptorum Group (APM). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. NLS Pharmaceutics Sonoma Pharmaceuticals Ensysce Biosciences Organovo PowerUp Acquisition Kazia Therapeutics Clearmind Medicine China Pharma Adial Pharmaceuticals Aptorum Group Bio-Path (NASDAQ:BPTH) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability. Which has more volatility and risk, BPTH or NLSP? Bio-Path has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Which has preferable earnings and valuation, BPTH or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ANLS PharmaceuticsN/AN/A-$12.17MN/AN/A Is BPTH or NLSP more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% NLS Pharmaceutics N/A N/A N/A Do insiders & institutionals have more ownership in BPTH or NLSP? 5.7% of Bio-Path shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer BPTH or NLSP? Bio-Path received 274 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. However, 57.14% of users gave NLS Pharmaceutics an outperform vote while only 53.01% of users gave Bio-Path an outperform vote. CompanyUnderperformOutperformBio-PathOutperform Votes28253.01% Underperform Votes25046.99% NLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Does the media prefer BPTH or NLSP? In the previous week, Bio-Path had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Bio-Path and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.43 beat Bio-Path's score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Neutral NLS Pharmaceutics Positive Do analysts rate BPTH or NLSP? Bio-Path currently has a consensus target price of $20.00, indicating a potential upside of 12,803.23%. Given Bio-Path's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Path is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBio-Path beats NLS Pharmaceutics on 7 of the 13 factors compared between the two stocks. Remove Ads Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E RatioN/A7.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.226.386.894.23Net Income-$16.08M$142.34M$3.20B$247.47M7 Day Performance-0.26%-5.15%-3.06%-2.29%1 Month Performance-13.79%-7.55%1.52%-5.81%1 Year Performance-96.24%-11.06%9.37%-0.96% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path1.5142 of 5 stars$0.16-8.8%$20.00+12,803.2%-96.2%$1.29MN/A0.0010Analyst ForecastNews CoverageGap UpNLSPNLS PharmaceuticsN/A$1.51flatN/A+622.2%$5.43MN/A0.006Short Interest ↓SNOASonoma Pharmaceuticals0.3654 of 5 stars$3.23-7.2%N/A+1,349.2%$5.22M$13.97M-0.80180Short Interest ↑News CoverageENSCEnsysce Biosciences1.0201 of 5 stars$3.65+5.8%N/A-72.6%$5.13M$2.23M-0.1310Short Interest ↓ONVOOrganovo0.9932 of 5 stars$2.99-4.8%N/A-80.5%$5.09M$122,000.00-3.5220Analyst ForecastStock SplitShort Interest ↓News CoveragePWUPPowerUp AcquisitionN/A$0.63-8.4%N/A-94.2%$4.90MN/A0.00N/ANews CoverageHigh Trading VolumeKZIAKazia Therapeutics2.87 of 5 stars$0.95-2.6%$11.50+1,110.4%-71.6%$4.79M$2.31M0.0012Short Interest ↑CMNDClearmind Medicine0.9674 of 5 stars$1.10-1.8%N/A-7.0%$4.69MN/A-0.59N/AShort Interest ↓Gap UpCPHIChina PharmaN/A$0.24+3.1%N/A-26.0%$4.68M$5.54M0.00250Analyst ForecastNews CoverageGap UpADILAdial Pharmaceuticals3.0221 of 5 stars$0.71-3.8%$8.00+1,026.8%-49.8%$4.67MN/A-0.2120Short Interest ↓Gap DownAPMAptorum Group1.5563 of 5 stars$0.90-2.2%N/A-90.7%$4.66M$430,000.000.0030Short Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies NLSP Alternatives SNOA Alternatives ENSC Alternatives ONVO Alternatives PWUP Alternatives KZIA Alternatives CMND Alternatives CPHI Alternatives ADIL Alternatives APM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
